Berenberg announced on Friday that it had raised its target price for bioMérieux from €114.5 to €122.2, while renewing its Buy recommendation on the stock.

In a research note, the German financial intermediary considers that the recent correction suffered by the share is unjustified, creating an attractive entry point for the stock.

In the analyst's view, the diagnostics specialist has a solid medium-term outlook, as demonstrated by the well-received investor day on April 9, and the management team has made clear the path it intends to take to achieve its objectives.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.